Identification of Calcium integrin binding protein 1 (CIB1) competitor

钙整合素结合蛋白 1 (CIB1) 竞争对手的鉴定

• 批准号: 10691120
• 负责人: Anton Simeonov
• 金额: $ 25.96万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10691120
• 关键词: Antiplatelet Drugs; Binding Proteins; Biological Assay; Blood Platelets; Calcium; Calcium Binding; Collaborations; Collection; Data; Exhibits; Growth; Impairment; Integrin Binding; Integrins; Mediating; Mus; Pharmaceutical Preparations; Signal Transduction; Testing; Thrombus; Validation; follow-up; high throughput screening; miniaturize; prevent; small molecule

This collaboration seeks to uncover small molecules capable of preventing the association of CIB1 and IIb3 as potential anti-platelet agents. During this period, the collaborative team utilized the previously optimized and miniaturized CIB1 assay to conduct a quantitative high-throughput screen of several of NCGC's small molecule collections. Identified hits were cherrypicked for initial validation using the primary assay, and were subsequently tested in follow-up assays to provide additional activity data.

这项合作旨在发现能够防止CIB1和IIB3成为潜在抗植物药物的小分子。 在此期间，协作团队利用了先前优化和微型CIB1测定法，对NCGC的几个小分子集合进行了定量的高通量屏幕。使用主要测定法将确定的命中选择用于初步验证，并随后在后续测定中测试以提供其他活动数据。